- The cobas BV/CV assay detects bacteria and yeast causing vaginitis using a single vaginal swab.
- Traditional methods like microscopy and pH testing often yield inaccurate results.
- Bacterial vaginosis affects 25% of women of reproductive age; candida vaginitis affects up to 75% once in their lifetime.
- The global sexual health market is valued at CHF 1.1 billion, with vaginitis as the primary growth driver at 26% annually.
Introduction
Roche has launched the cobas BV/CV assay, a new PCR test designed to improve the diagnosis of vaginitis by detecting bacteria and yeast responsible for bacterial vaginosis and candida vaginitis.
Diagnostic Challenges
Traditional diagnostic methods, such as microscopy and pH testing, often produce inaccurate results due to the non-specific symptoms of vaginitis, leading to delays in treatment or inappropriate therapies.
Test Advantages
The cobas BV/CV assay offers faster and more accurate diagnosis using a single vaginal swab, eliminating the need for additional samples and enabling targeted therapies for patients.
Market Impact
Bacterial vaginosis affects approximately 25% of women of reproductive age, while up to 75% of women experience candida vaginitis at least once in their lifetime. The global sexual health market is valued at CHF 1.1 billion, with vaginitis as the primary growth driver at 26% annually.
Healthcare Efficiency
The assay enhances the capabilities of Roche's cobas systems by allowing simultaneous testing for BV, CV, and other sexually transmitted infections, supporting faster and more efficient workflows in sexual health clinics, hospitals, and laboratories.
